Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp. develops clinical-stage biotechnology programs centered on PAS-004, a next-generation macrocyclic MEK inhibitor. Company news for KTTAW, the Nasdaq-listed warrants to purchase Pasithea common stock, typically covers PAS-004 clinical and regulatory updates in neurofibromatosis type 1-associated plexiform neurofibromas, MAPK pathway-driven advanced solid tumors, ALS, and other disease areas tied to RASopathies and CNS disorders.
Recurring developments include FDA designations, clinical pharmacokinetic, pharmacodynamic, safety, and tolerability data, research grants, healthcare conference presentations, and capital actions such as public equity offerings. The coverage also reflects Pasithea's status as a public biotechnology issuer with common stock and warrants listed on The Nasdaq Capital Market.
Pasithea Clinics has launched IV ketamine infusion therapy in Knightsbridge, London, targeting mental health disorders. This initiative is part of Pasithea Therapeutics Corp.'s broader mission to find effective treatments for psychiatric conditions. The therapy is particularly aimed at treatment-resistant depression and PTSD, with studies indicating a clinical response rate of up to 70%. Partnering with ZEN Healthcare in the U.K. and The IV Doc in the U.S., Pasithea is expanding access to these treatments, addressing the growing mental health crisis.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced a partnership with ZEN Healthcare to launch ketamine infusion therapy in Central London for patients with treatment-resistant mental health disorders. This initiative aims to address the growing need for innovative treatments amid rising mental health cases exacerbated by the pandemic. The therapy promises rapid efficacy in conditions like treatment-resistant depression and PTSD. Pasithea recently raised $24 million during its IPO, enhancing its capacity to expand treatment networks in the U.K. and the U.S.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced a collaboration with Evotec, a leading drug development company, to advance its initial drug candidate targeting psychiatric disorders. This partnership marks the start of a new chemical entity development program focused on neuroinflammatory pathways linked to depression and schizophrenia. The collaboration aims to leverage Evotec's expertise to expedite the drug's progression toward clinical trials. The company's strategic focus is on developing innovative treatments for psychiatric conditions and establishing psychiatric clinics in the UK and US.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has announced that CEO Dr. Tiago Reis Marques will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 10:10 AM ET. The live presentation will be available via webcast and archived for 30 days on the company's website. Pasithea focuses on developing treatments for psychiatric and neurological disorders, targeting pathophysiology to improve efficacy and tolerability compared to conventional therapies. The company also provides business support services for anti-depression clinics in the UK and the US.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has successfully closed its initial public offering of 4,800,000 units at a price of $5.00 per unit, generating approximately $24.0 million in gross proceeds. Each unit consists of one share of common stock and one warrant for an additional share. The company's stock and warrants began trading on Nasdaq on September 15, 2021. The offering aims to support the company’s focus on discovering new treatments for psychiatric and neurological disorders.